Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 6/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13416621 | 1.00 | CHRNB4 (0.43) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17735692 | 1.00 | CHRNB4 (0.43) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12889418 | 0.98 | CHRNB4 (0.42) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21398764 | 0.98 | CHRNB4 (0.42) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20259549 | 0.98 | CHRNB4 (0.42) | CHRNB4CHRNA3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2756894 | 0.92 | — | — | |
| SCHEMBL1615410 | 0.92 | — | — | |
| SCHEMBL6891743 | 0.92 | — | — | |
| SCHEMBL7600258 | 0.81 | — | — | |
| SCHEMBL13620950 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018002-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| US-20230381172-A1 | COMBINATIONS OF BCL-2 INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | ZENO MANAGEMENT, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381172-A1 | COMBINATIONS OF BCL-2 INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | ZENO MANAGEMENT, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | SAIL BIOMEDICINES, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382894-A1 | CCR4 ANTAGONISTS | CHEMOCENTRYX, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | GENENTECH, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-04-01 | — | — | US | disclosed |
| US-7652153-B2 | Use in controlling apoptosis, as antiinflammatory agents, in treating autoimmune disease, as antiischemic agents, in treating cardiovascular disorders; for example, (S,S)-3-[2-(3-Acetylamino-2-oxo-2H-pyridin-1-yl)-butyrylamino]-4-oxo-5-(2,3,5,6-tetrafluoro-phenoxy)-pentanoic acid | VERTEX PHARMACEUTICALS INCORPORATED | 2010-01-26 | — | — | US | disclosed |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| US-20090227576-A1 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| US-7553846-B2 | 2-alkylbenzoxazole carboxamides as 5-HT3 modulators | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7528148-B2 | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors | GLAXO GROUP LIMITED (GB) | 2009-05-05 | — | — | US | disclosed |
| US-20090082313-A1 | Multikinase Inhibitors for Use in the Treatment of Cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090048429-A1 | Processes and intermediates | VERTEX PHARMACEUTICALS INCORPORATED | 2009-02-19 | — | — | US | disclosed |
| US-20080214601-A1 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | AMR TECHNOLOGY, INC. (US) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230382894-A1 | CCR4 ANTAGONISTS | CCR4, CCR1, CCR3 | CHRNB4 64/4885CHRNA3 155/4885SLC6A2 3170/4885 |
| US-12018002-B2 | Certain chemical entities, compositions, and methods | BRAF, PIK3CA, PLK1 | CHRNB4 4425/4885CHRNA3 4546/4885SLC6A2 4646/4885 |
| US-20230381182-A1 | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same | AHR, CD274, ARNT | CHRNB4 2626/4885CHRNA3 2631/4885SLC6A2 3969/4885 |
| US-20090082313-A1 | Multikinase Inhibitors for Use in the Treatment of Cancer | EGFR, ERBB3, FLT3 | CHRNB4 4873/4885CHRNA3 4856/4885SLC6A2 4695/4885 |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | CHRNB4 1401/4885CHRNA3 2425/4885SLC6A2 3626/4885 |
| US-11827639-B2 | TDO2 and IDO1 inhibitors | IDO1, TDO2, IDO2 | CHRNB4 3970/4885CHRNA3 3594/4885SLC6A2 630/4885 |
| US-20090291917-A1 | Boron-Containing Small Molecules as Anti-Inflammatory Agents | NFKBIA, LITAF, CD68 | CHRNB4 3931/4885CHRNA3 4529/4885SLC6A2 3448/4885 |
| US-20090048429-A1 | Processes and intermediates | CASP1, CASP3, CASP5 | CHRNB4 4530/4885CHRNA3 4378/4885SLC6A2 3409/4885 |
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | CHRNB4 3755/4885CHRNA3 4114/4885SLC6A2 361/4885 |
| US-20230381172-A1 | COMBINATIONS OF BCL-2 INHIBITORS WITH CHEMOTHERAPEUTIC AGENTS | BCL2, BAD, BAK1 | CHRNB4 4831/4885CHRNA3 4784/4885SLC6A2 3770/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | CHRNB4 3178/4885CHRNA3 3598/4885SLC6A2 2569/4885 |
| US-20100081693-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | NR2C2, NR4A3, NR0B2 | CHRNB4 944/4885CHRNA3 265/4885SLC6A2 3658/4885 |
| US-20090227576-A1 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | HTR3E, HTR3C, HTR3A | CHRNB4 1730/4885CHRNA3 343/4885SLC6A2 498/4885 |
| US-20240067642-A1 | COMPOUNDS AND USES THEREOF | VHL, TFEB, BECN1 | CHRNB4 4684/4885CHRNA3 4646/4885SLC6A2 3634/4885 |
| US-20080214601-A1 | 2-ALKYLBENZOXAZOLE CARBOXAMIDES AS 5HT3 MODULATORS | HTR3E, HTR3C, HTR3A | CHRNB4 1730/4885CHRNA3 343/4885SLC6A2 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.